Lion Biotechnologies Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
March 03, 2015 09:10 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, March 3, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes...
Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference
March 02, 2015 08:30 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, March 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35th Annual Healthcare...
Lion Biotechnologies Prices Public Offering of Common Stock
February 26, 2015 08:23 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes...
Lion Biotechnologies Announces Public Offering of Common Stock
February 25, 2015 16:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes...
Lion Biotechnologies Announces Its Listing on the Nasdaq Global Market
February 24, 2015 16:45 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating...
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
February 17, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
February 11, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
February 10, 2015 08:15 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma
February 02, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications
January 26, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...